Doxofylline: A "Novofylline"

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 4, 2010, Pages 231-234

  Page, Clive P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; COPD; Doxofylline; Lung disease; Theophylline; Xanthines

Indexed keywords

AMINOPHYLLINE; BAMIFYLLINE; BRONCHODILATING AGENT; DOXOFYLLINE; GLUCOCORTICOID; PLACEBO; THEOPHYLLINE; XANTHINE DERIVATIVE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG STRUCTURE; FORCED EXPIRATORY FLOW; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INSOMNIA; LOW DRUG DOSE; LUNG DISEASE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SPIROMETRY; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; LUNG DISEASES; THEOPHYLLINE;

EID: 77953133513     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.04.002     Document Type: Review

References (38)

1. Barnes P.J. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 167 (2003) 813-818
2. Sullivan P., Bekir S., Jaffar Z., Page C.P., Jeffery P., and Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343 (1994) 1006-1008
3. Nicholson C.D., and Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulm Pharmacol 7 1 (1994) 1-17
4. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 99 (2002) 8921-8926
5. Horrigon L.A., Kelly D.P., and Connor T.S. Caffeine suppresses TNF-α production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol (2004) 1409-1417
6. Global Initiative for Asthma. Global strategy for asthma management and prevention.
7. Lim S., Jatakanon A., Gordon D., Macdonald C., Chung K.F., and Barnes P.J. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 55 (2000) 837-841
8. Ukena D., Harnest U., Sakalauskas R., Magyar P., Vetter N., Steffen H., et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 10 (1997) 2754-2760
9. GOLD Global Initiative for Chronic Obstructive Lung Disease. Executive summary. Based on an April 1998 NHLBI/WHO Workshop, updated 2004. Available at:. http://www.goldcopd.com/ [accessed 17.01.06]
10. Kelloway J.S., Wyatt R.A., and Adilis S.A. Comparison of patients compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 154 (1994) 1349-1352
11. Yasui K., Agematsu K., Shinozaki K., Hokibara S., Nagumo H., Nakazawa T., et al. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 67 (2000) 529-535
12. Kofman J., Grosclaude M., Ouechni M.M., and Peyrin-Fayalle M. Comparative effects of bamifylline and theophylline on allergic bronchospasm induced by the proactive inhalation test: a double blind cross over study. Poumon Coeur 38 (1982) 197-202
13. Pozzi E. Acebrofylline: an airway regulator and anti-inflammatory agent. Monaldi Arch Chest Dis 67 (2007) 106-115
14. Dini F.L., and Cogo R. Doxofylline: a new generation xanthine bronchodilator derived and major cardiovascular side effects. Curr Med Res Opin 16 (2001) 258-268
15. Boswell-Smith V., Cazzola M., and Page C.P. Are phoshpodiesterase inhibitors just more theophylline?. J Allergy Clin Immunol (2006) 1237-1243
16. Fabbir L.M., Calverley P.M., Izquirado-Alonso J.L., Bundschuh D.S., Brose M., Martinez F.J., et al. Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomized trials. Lancet 374 (2009) 695-703
17. Calverley P.M., Rabe K.F., Goehring U.M., Kriastiansen S., Fabbri L.M., and Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 374 (2009) 685-694
18. Cirillo R., Barone D., and Franzone J.S. Doxofylline, an anti-asthmatic drug lacking afficnity for adenosine receptors. Arch Int de Pharmacodynamic et Therapie 295 (1988) 221-237
19. Franzone J.S., Cirillo R., and Reboomi M.C. Doxofylline differs from methylxanthines in its movement of cytosolic calcium. Int J Tissue React 18 (1991) 131-138
20. Franzone J.S., Cirillo R., and Biffignandi P. Doxofylline exerts a prophylactic effect against bronchconstriction and pleurisy induced by PAF. Eur J Pharmacol 165 (1989) 269-277
21. Sugeta A., Imai T., Idaira S., Hirokoshi M., Okamoto M., and Adachi M. Effects of theophylline and doxofylline on airway responsiveness in dogs. Arerugi 46 (1997) 7-15
22. Zhou B., Cai S.T., Zou F., Cai C.Q., and Zhoo H.J. Effect of doxofylline on calcium-activated potassium channels in human peripheral blood eosinophils. Clin J Tuberc Resp Dis 28 (2005) 817-819
23. Dolcetti A., Osella D., De Fillipis G., Carmuccio C., and Grossi E. Comparison of intravenously administered doxofylline and placebo for the treatment of severe acute airways obstruction. J Int Med Res 16 (1988) 264-269
24. Melillo G., Balzano G., Jodice F., De Felice A., Campisi V., Capone M., et al. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial. Int J Clin Pharmacol Res 9 (1989) 397-405
25. Bagnato G., Fodale P., and Bottari M. Clinical evaluation of doxofylline sachets in a pediatric population. Riv Eur Sci Med Farmacol 11 (1989) 359-363
26. Bagnato G.F. Tolerability of doxofylline in the maintenance therapy of paediatric patients with bronchial asthma. Eur Rev Med Pharmacol Sci 3 (1999) 255-260
27. Goldstein M.F., and Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma-a double blind, randomized, placebo controlled-multicentre clinical trial. Med Sci Monit 8 (2002) 297-304
28. Cogo R., and Castronuovo A. Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis. Eur Rev Med Pharmacol Sci 4 (2000) 15-20
29. Sankar J., Lodhan R., and Kabra S.K. Doxofylline: the next generation methylxanthine. Indian J Pediatr 75 3 (March 2008) 57-60
30. Zang J.X., Lin H.Q., Chen J.S., Yuang H.L., and Wu S.Y. Clinical study on doxofylline in treatment with children with acute asthma attack. Chin J Paediatr 42 (2004) 143-144
31. Lazzaroni M., Grossi E., and Banchi P.G. The effect of intravenous doxofylline or aminophylline on gastric secretion in duodenal ulcer patients. Aliment Pharmacol Ther 4 (1990) 643-649
32. Dini F.L. Chronotropic and arrhythmogenic effects of two methylxanthine bronchodilators, doxofylline and theophylline, evaluated by holter monitoring. Cur Ther Res (1991) 978-985
33. Giorgis G.E., Galietti F., Ardizzi A., Barberis S., Giove S., Gai R., et al. Doxofyllina + procaterolo versus aminofillina + procaterolo: valutazione elettrocardiografica dinamica delle variazioni del ritmo. Acta Toxiocologica e Therapeutica 11 (1990) 101-107
34. Cipri A., Pozzar R., and Dini F.L. Alterazioni del ritmo cardiaco in pazienti con broncopneumopatia cronica ostruttiva: effetto di differenti farmaci metilxantinici. Estratto da Minerva Cardioangiologica 40 1-2 (1992) 31-39
35. Sacco C., Barthiroli A., Gross E., and Donner C.F. The effects of doxofylline versus theophylline on sleep architecture in COPD patients. Monaldi Arch Chest Dis 50 (1995) 98-103
36. Franzone J.S., Cirillo R., and Barone D. Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals. Drugs Exp Clin Res 14 (1988) 479-489
37. Patent application No. WO 2009/112436 A1.
38. Orefice U., Struzzo P.L., Dini F.L., and Biffignandi P. Valutazione randomizzata e controllata verso placebo dell'efficacia terapeutica di doxofillina e bamifillina in pazienti affetti da broncopneumopatia cronica ostruttiva. Clinica e Terapia II (1991) 1-5